"According to The Guardian, one of the two studies, the Pathways Trial, will randomly divide some 226 participants between the ages of 10 and 16 into two groups. One will receive puberty blocking medication immediately, while the second will receive the medication after a year. Participants' quality of life, emotional well-being, and physical development will be compared to those of a third group, which will not receive puberty blockers."
"In a November 22 statement, Chay Brown, healthcare director for U.K. trans rights nonprofit TransActual, said that the study "is the result of an ideological view at the very top of the NHS that being trans is a 'less desirable outcome.'" In the same press release, TransActual reiterated its position that the U.K. Department of Health and Social Care's decision to ban puberty blockers for trans minors, but not for the treatment of conditions like precocious puberty in cisgender minors, is "discriminatory" and not based in actual scientific evidence."
Two NHS studies were announced to examine the effects of puberty blockers on transgender young people following the Cass Review and a government decision limiting access for minors. The Pathways Trial will randomize about 226 participants aged 10–16 into immediate treatment, treatment delayed by one year, and a no-treatment comparison group, measuring quality of life, emotional well-being, and physical development. The study has ethics committee approval and regulatory clearance from the Health Research Authority and MHRA. The trial has drawn criticism from advocates across the spectrum, with claims of unethical design, ideological bias, and discriminatory policy differentials versus cisgender treatments for precocious puberty.
Read at LGBTQ Nation
Unable to calculate read time
Collection
[
|
...
]